JW Pharmaceutical
001060
Company Profile
Business description
JW Pharmaceutical is active in the healthcare sector. It has been one of the leading companies in the pharmaceutical market on a global basis. Its original medicine and medical supply pipeline include Livalo, Thrupas, Sigmart and Actemra. It also develops low-protein and low-salt diet food for patients suffering from chronic renal insufficiency as well as general Pharmaceuticals and health care products.
Contact
2477, Nambusunhwan-ro
Seocho-gu
KORT: +82 28406777
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,087
Stocks News & Analysis
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
stocks
New production imminent for undervalued ASX gas play
LNG project receives first commissioning gas.
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,290.60 | 6.80 | 0.07% |
| CAC 40 | 8,174.20 | 14.39 | -0.18% |
| DAX 40 | 23,830.99 | 441.20 | -1.82% |
| Dow JONES (US) | 46,190.61 | 238.37 | 0.52% |
| FTSE 100 | 9,354.57 | 81.52 | -0.86% |
| HKSE | 25,766.24 | 519.14 | 2.06% |
| NASDAQ | 22,679.97 | 117.44 | 0.52% |
| Nikkei 225 | 48,846.69 | 1,264.54 | 2.66% |
| NZX 50 Index | 13,301.09 | 11.88 | 0.09% |
| S&P 500 | 6,664.01 | 34.94 | 0.53% |
| S&P/ASX 200 | 8,994.30 | 6.10 | 0.07% |
| SSE Composite Index | 3,862.60 | 22.84 | 0.59% |